• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 4 filed by Director Cassirer Aurora

    1/2/25 9:18:10 PM ET
    $NAOV
    Industrial Specialties
    Health Care
    Get the next $NAOV alert in real time by email
    SEC FORM 4 SEC Form 4
    FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940
    OMB APPROVAL
    OMB Number: 3235-0287
    Estimated average burden
    hours per response: 0.5
      
    Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
      
    Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
    1. Name and Address of Reporting Person*
    Cassirer Aurora

    (Last) (First) (Middle)
    C/O NANOVIBRONIX, INC.
    969 PRUITT AVE

    (Street)
    TYLER TX 77569

    (City) (State) (Zip)
    2. Issuer Name and Ticker or Trading Symbol
    NanoVibronix, Inc. [ NAOV ]
    5. Relationship of Reporting Person(s) to Issuer
    (Check all applicable)
    X Director 10% Owner
    Officer (give title below) Other (specify below)
    3. Date of Earliest Transaction (Month/Day/Year)
    12/30/2024
    4. If Amendment, Date of Original Filed (Month/Day/Year)
    6. Individual or Joint/Group Filing (Check Applicable Line)
    X Form filed by One Reporting Person
    Form filed by More than One Reporting Person
    Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
    1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V Amount (A) or (D) Price
    Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
    Option to Purchase Common Stock $0.5995 12/30/2024 A 20,000 (1) 12/30/2034 Common Stock 20,000 $0 20,000 D
    Explanation of Responses:
    1. 100% of the options vested on the date of grant in accordance with that certain option agreement entered into by and between the Issuer and the reporting person and the NanoVibronix, Inc. 2024 Long-Term Incentive Plan.
    /s/ Aurora Cassirer 01/02/2025
    ** Signature of Reporting Person Date
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    Get the next $NAOV alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $NAOV

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $NAOV
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • NanoVibronix Regains Nasdaq Compliance

      NanoVibronix, Inc. (NASDAQ:NAOV) (the "Company" or "NanoVibronix"), a medical technology company specializing in non-invasive therapeutic devices, today announced that on April 9, 2025, Nasdaq formally notified the Company that it has evidenced full compliance with all criteria for continued listing on The Nasdaq Capital Market, including the $1.00 bid price and $2.5 million stockholders' equity requirements. Accordingly, the previously disclosed Nasdaq listing matter has been closed. Pursuant to Listing Rule 5815(d)(4)(B), the Company will be subject to a Mandatory Panel Monitor until April 9, 2026. About NanoVibronix, Inc. NanoVibronix, Inc. (NASDAQ:NAOV) is a medical device company hea

      4/11/25 8:00:00 AM ET
      $NAOV
      Industrial Specialties
      Health Care
    • NanoVibronix Announces Renewal and Expansion of Distribution Agreement with Dukehill Healthcare Pty Ltd in Australia

      Publication of Independent Study Heightens Demand for UroShield NanoVibronix, Inc. (NASDAQ:NAOV) (the "Company" or "NanoVibronix"), a medical technology company specializing in non-invasive therapeutic devices, today announced the renewal and expansion of its exclusive three-year distribution agreement with Dukehill Healthcare Pty Ltd. ("Dukehill"). Dukehill, with its Head Office in Queensland, has primarily focused its clinical projects and sales efforts within the state and in New South Wales. However, the recent expansion of the agreement with the Company now extends across all Australian States, with notable growth in South Australia and Victoria. This surge follows an increasing numb

      4/1/25 8:00:00 AM ET
      $NAOV
      Industrial Specialties
      Health Care
    • Successful Independent Study of the NanoVibronix UroShield® Device Published in the Australian and New Zealand Continence Journal

      UroShield Cited as Effective in Preventing CAUTIs and Blockages, Having a Major Impact on Quality of Life and Reducing Healthcare Resource Costs NanoVibronix, Inc. (NASDAQ:NAOV) (the "Company"), a medical technology company specializing in non-invasive therapeutic devices, today announced that an independent health service study of its UroShield® is published in The Australian and New Zealand Continence Journal. The study highlights UroShield's effectiveness in preventing catheter-associated urinary tract infections (CAUTIs) and recommends its adoption for appropriate patients with indwelling urinary catheters (IUCs). Researchers found that patients using UroShield experienced an 86% redu

      3/14/25 8:00:00 AM ET
      $NAOV
      Industrial Specialties
      Health Care

    $NAOV
    Leadership Updates

    Live Leadership Updates

    See more
    • NanoVibronix Announces Results of Annual Meeting of Stockholders Held Today

      NanoVibronix, Inc. (NASDAQ:NAOV) (the "Company"), a medical device company utilizing the Company's proprietary and patented low intensity surface acoustic wave (SAW) technology, announced that the Company's 2022 annual meeting of stockholders (the "Annual Meeting") was held today virtually and broadcast live at www.virtualshareholdermeeting.com/NAOV2022. The following resolutions submitted for stockholder approval were adopted: Election of the eight director nominees (Aurora Cassirer, Christopher Fashek, Michael Ferguson, Martin Goldstein, M.D., Harold Jacob, M.D., Thomas Mika, Brian Murphy, and Maria Schroeder) to serve on the Company's board of directors (the "Board"), for a term of on

      12/15/22 4:05:00 PM ET
      $NAOV
      Industrial Specialties
      Health Care
    • NanoVibronix Reports First Quarter 2022 Financial Results

      Expanded Distribution, Entry into New Geographic Markets and Regulatory Approvals Advancing Efforts Towards Full Commercialization NanoVibronix, Inc., (NASDAQ:NAOV), a medical device company utilizing the Company's proprietary and patented low intensity surface acoustic wave (SAW) technology, today reported its financial results for the quarter ended March 31, 2022. First Quarter 2022 Financial and Recent Business Highlights Revenue of $272,000, an increase of 164% compared to the prior year period Significant backlog of orders to be filled in Q2 Supply chain challenges are expected to abate moving into the second half of 2022 Submitted a 510(k) application to the U.S. Food and Dr

      5/17/22 8:30:00 AM ET
      $NAOV
      Industrial Specialties
      Health Care
    • Cerro de Pasco Announces MCTO and New Chief Financial Officer

      MONTREAL, April 29, 2022 /CNW Telbec/ - Cerro de Pasco Resources Inc. (CSE:CDPR) (Frankfurt: N8HP) ("CDPR" or the "Company") announces that it has applied to the Autorité des marchés financiers (Québec) (the "AMF"), as principal regulator of the Company, and expects to be granted a management cease trade order (the "MCTO") on May 2, 2022, pursuant to Policy Statement 12-203 Respecting Management Cease Trade Orders ("PS 12-203"). Under the MCTO, the Company's Chief Executive Officer (CEO), Chief Financial Officer (CFO) and directors may not trade in securities of the Company until such time as the Company files its audited consolidated financial statements, its management's discussion and ana

      4/29/22 3:28:00 PM ET
      $GMBL
      $NAOV
      Services-Misc. Amusement & Recreation
      Consumer Discretionary
      Industrial Specialties
      Health Care

    $NAOV
    Financials

    Live finance-specific insights

    See more
    • NanoVibronix Announces Distribution of Series F Preferred Stock to Holders of its Common Stock

      NanoVibronix, Inc. (NASDAQ:NAOV) ("Nano" or the "Company"), a medical device company utilizing the Company's proprietary and patented low intensity surface acoustic wave (SAW) technology, today announced that its Board of Directors declared a dividend of one one-thousandth of a share of newly designated Series F Preferred Stock, par value $0.001 per share, for each outstanding share of the Company's common stock held of record as of 5:00 p.m. Eastern Time on October 14, 2022. The shares of Series F Preferred Stock will be distributed to such recipients at 5:00 p.m. Eastern Time on October 17, 2022. The outstanding shares of Series F Preferred Stock will vote together with the outstanding sh

      9/14/22 9:25:00 AM ET
      $NAOV
      Industrial Specialties
      Health Care

    $NAOV
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by NanoVibronix Inc.

      SC 13G/A - NanoVibronix, Inc. (0001326706) (Subject)

      11/14/24 5:17:34 PM ET
      $NAOV
      Industrial Specialties
      Health Care
    • SEC Form SC 13G filed by NanoVibronix Inc.

      SC 13G - NanoVibronix, Inc. (0001326706) (Subject)

      2/14/24 3:45:41 PM ET
      $NAOV
      Industrial Specialties
      Health Care
    • SEC Form SC 13G/A filed

      SC 13G/A - NanoVibronix, Inc. (0001326706) (Subject)

      2/16/21 3:49:24 PM ET
      $NAOV
      Industrial Specialties
      Health Care

    $NAOV
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Chief Executive Officer Murphy Brian M

      4 - NanoVibronix, Inc. (0001326706) (Issuer)

      1/3/25 4:05:16 PM ET
      $NAOV
      Industrial Specialties
      Health Care
    • SEC Form 4 filed by Director Mika Thomas

      4 - NanoVibronix, Inc. (0001326706) (Issuer)

      1/2/25 9:26:30 PM ET
      $NAOV
      Industrial Specialties
      Health Care
    • SEC Form 4 filed by Chief Financial Officer Brown Stephen Russell

      4 - NanoVibronix, Inc. (0001326706) (Issuer)

      1/2/25 9:25:07 PM ET
      $NAOV
      Industrial Specialties
      Health Care

    $NAOV
    SEC Filings

    See more
    • Amendment: SEC Form S-1/A filed by NanoVibronix Inc.

      S-1/A - NanoVibronix, Inc. (0001326706) (Filer)

      4/29/25 5:30:36 PM ET
      $NAOV
      Industrial Specialties
      Health Care
    • Amendment: SEC Form S-1/A filed by NanoVibronix Inc.

      S-1/A - NanoVibronix, Inc. (0001326706) (Filer)

      4/22/25 5:24:40 PM ET
      $NAOV
      Industrial Specialties
      Health Care
    • NanoVibronix Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation, Other Events, Financial Statements and Exhibits

      8-K - NanoVibronix, Inc. (0001326706) (Filer)

      4/11/25 8:00:30 AM ET
      $NAOV
      Industrial Specialties
      Health Care